Dormant
OTLY · Oatly Group AB
Last analysed ·
Current thesis
Oatly’s guidance-led recovery failed its published $13.00 weekly price test at the $12.71 close on 2026-09-11. The next quarterly report must establish whether the operating recovery survives through confirmation of July’s revenue-growth and adjusted-EBITDA guidance.
Kill line
A weekly close below $13.00 invalidates the published post-guidance recovery thesis. This condition was met by the $12.71 close on 2026-09-11; the threshold remains unchanged.
Pick status
Open commitment scored if the kill line above fires How this is scored →Latest analysis and events for OTLY —
As of 13 September 2026, the latest FrontierPicks analysis for Oatly Group AB (OTLY): Oatly’s guidance-led recovery failed its published $13.00 weekly price test at the $12.71 close on 2026-09-11. The next quarterly report must establish whether the operating recovery survives through confirmation of July’s revenue-growth and adjusted-EBITDA guidance.
Kill line: A weekly close below $13.00 invalidates the published post-guidance recovery thesis. This condition was met by the $12.71 close on 2026-09-11; the threshold remains unchanged.
Current Thesis
Oatly’s guidance-led recovery has failed its published price test: the 2026-09-11 close of $12.71 breached the $13.00 weekly threshold, while the next quarterly report must establish whether the operating recovery survives. The market thesis rested on the 2026-07-22 increase in full-year constant-currency revenue growth guidance to 8–10%, alongside unchanged adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) guidance of $25–35 million. Oatly’s Q2 release.
For that post-guidance price recovery, the narrative is dead — the week ended 2026-09-11 below the threshold published on 2026-08-30. This classification is an inference from the observed price breach; it does not establish that the company’s revenue guidance has failed. The threshold remains $13.00 rather than moving lower after the breach.
Bullish and bearish views on Oatly Group AB
The model's bull view on Oatly Group AB (OTLY), in brief: Revenue supports the operating recovery. The bear view: The published floor has broken. The adjusted reference series records a $12.71 close on Friday, 2026-09-11, below the $13.00 weekly invalidation condition in the 2026-08-30 dossier. The prior price-supported recovery case is therefore invalidated. Borrowings constrain the… Both cases follow in full.
Bull Case
- Revenue supports the operating recovery. Oatly reported Q2 2026 revenue of $240.1 million on 2026-07-22, up 15.2% reported and 12.7% at constant currency. These results support the operating component of the original thesis. Q2 results.
- Profitability crossed into positive territory. The 2026-07-22 release reported Q2 adjusted EBITDA of $0.4 million and gross margin of 33.9%. Positive adjusted EBITDA is measured evidence, although the same quarter’s $31.3 million net loss limits the profitability claim. Q2 results.
Bear Case
- The published floor has broken. The adjusted reference series records a $12.71 close on Friday, 2026-09-11, below the $13.00 weekly invalidation condition in the 2026-08-30 dossier. The prior price-supported recovery case is therefore invalidated.
- Borrowings constrain the recovery case. Oatly disclosed $517.8 million of total borrowings and $44.6 million of cash at 2026-06-30. These are historical company balances; they do not establish current liquidity or an imminent financing. Q2 results.
Setup & Price Structure
The 2026-09-11 adjusted reference data show a three-month price increase of 55.4%, a close 29.7% below the $18.09 52-week high, and a 14-period relative strength index (RSI) of 33.5. The positive three-month change coexists with the failed $13.00 threshold. No current moving-average value is available to substantiate support at a rising average.
Retail attention is observable but cannot establish crowding: a dated 2026-09-11 discussion on r/ValueInvesting presented an Oatly recovery argument. This isolated observation is too small a sample to support a claim about expanding participation, concentrated ownership or a squeeze. Public discussion.
The analyst evidence also lacks a fresh dated revision: Stock Analysis’s forecast page retrieved on 2026-09-13 identifies 2026-07-23 as its latest target update. That observation dates the displayed coverage; it does not prove that no other analyst has published since. Analyst forecast table.
Catalyst Calendar (next 30 days)
For 2026-09-13 through 2026-10-13, no confirmed company catalyst was identified in the retrieved company releases and event listings. The absence of an identified event is not itself a catalyst. Company releases, event calendar.
- ~2026-10-28, estimated: Q3 results. Stock Analysis lists this date as of its 2026-09-10 page update; company confirmation was not identified. This later event matters because the next report can test the July revenue-growth and adjusted-EBITDA guidance. Earnings calendar listing.
What Would Change Our Mind
The loss of the published recovery floor has already settled the original market test: a weekly close below $13.00 occurred with the $12.71 close on 2026-09-11. A subsequent weekly close above $13.00 would establish a reclaim, but would not erase that recorded invalidation.
A renewed operating case would require the next quarterly disclosure to retain the 8–10% constant-currency growth outlook and $25–35 million adjusted-EBITDA range issued on 2026-07-22. A reduction below either range would contradict that proposed recovery condition.
Correlation Notes
The 2026-08-30 public dossier cited a 2026-08-17 report linking Oatly weakness with Beyond Meat’s reverse-split reaction. That episode is too small a sample to establish a stable peer correlation. This remains a single-company operating recovery assessment; the supplied record contains no return series establishing participation in a broader consumer or small-cap rotation.
Notes
- Foreign private issuer: reports on Form 6-K and 20-F, not 10-Q/10-K.
- Reports in USD while the largest growth region is European, so reported and constant-currency growth diverge every quarter.
- 9.25% Convertible Senior PIK Notes due 2028-09-14 accrete interest rather than pay cash, so principal compounds absent repurchase.
- Capital stack is multi-currency: SEK 1,700M Nordic bonds and a SEK 750M super senior RCF alongside the USD convertibles.
- Sell-side coverage is thin and target sets disagree: Barclays at $14 on 2026-07-23 against a five-analyst $19.50 average shown on stockanalysis.com on 2026-08-30.
- 31.91M shares outstanding gives a small float; single-print moves and index/screen flows can dominate short-run price action.
Related · shared themes
OSCR
Oscar Health, Inc.
Oscar Health's higher earnings outlook and quantified 2027 pricing support a post-Investor-Day rerating. A weekly close above $32.76 before a weekly close below $29.83 would complete the price-confirmation test; the September 18, 2026 close of $32.13 leaves it unresolved.
CNC
Centene Corporation
Centene's margin-repair case requires sustained earnings guidance and a weekly close above $68.72 by its 2026-10-27 results. September's reaffirmation supports the earnings leg, but a weekly close below $65 or withdrawal or reduction of fiscal 2026 adjusted EPS guidance above $4.80 invalidates the case.
HNGE
Hinge Health, Inc.
Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.
HUM
Humana Inc.
Humana's Medicare Advantage margin-recovery story faces a renewed price test: an adjusted daily close above $409.80 before a daily close below $383. The September 1, 2026 earnings reaffirmation supports stability, while October Star Ratings test the quality-bonus premise.
See also · stocks to watch